Come a long way, still a ways to go: from predicting and preventing fluoropyrimidine toxicity to increased efficacy?

Seid Hamzic^{1

2}, Ursula Amstutz¹, Carlo R Largiadèr¹

Affiliations

¹ University Institute of Clinical Chemistry, Inselspital Bern University Hospital, University of Bern, Inselspital INO-F, CH-3010 Bern, Switzerland.
² Graduate School for Cellular & Biomedical Sciences, University of Bern, Freiestrasse 1, CH-3012 Bern, Switzerland.

Editorial

Seid Hamzic et al. Pharmacogenomics. 2018.

. 2018 Jun 1;19(8):689-692.

doi: 10.2217/pgs-2018-0040. Epub 2018 May 22.

Seid Hamzic^{1

2}, Ursula Amstutz¹, Carlo R Largiadèr¹

¹ University Institute of Clinical Chemistry, Inselspital Bern University Hospital, University of Bern, Inselspital INO-F, CH-3010 Bern, Switzerland.
² Graduate School for Cellular & Biomedical Sciences, University of Bern, Freiestrasse 1, CH-3012 Bern, Switzerland.

No abstract available

Keywords: 5-FU; BSA-based dosing; DPYD; TDM; capecitabine; pharmacogenetics.

Publication types